Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).
Pellegrino B, Tommasi C, Serra O, Gori S, Cretella E, Ambroggi M, Frassoldati A, Bisagni G, Casarini C, Bria E, Carbognin L, Fiorio E, Mura A, Zamagni C, Gianni L, Zambelli A, Montemurro F, Tognetto M, Todeschini R, Missale G, Campanini N, Silini EM, Maglietta G, Musolino A. Pellegrino B, et al. J Immunother Cancer. 2023 Nov 28;11(11):e007667. doi: 10.1136/jitc-2023-007667. J Immunother Cancer. 2023. PMID: 38016718 Free PMC article. Clinical Trial.
Twelve ESMO Congress 2022 breakthroughs: practicing oncologists' perceptions and potential application on presented data.
van Halteren HK, Bennouna J, Brasiuniene B, Tomas AJC, Trinidad AMG, Indini A, Liposits G, Pellegrino B, Popovic L, Tan A, Vidra R, Strijbos M; Practising Oncologists Working Group. van Halteren HK, et al. Among authors: pellegrino b. ESMO Open. 2023 Feb;8(1):100773. doi: 10.1016/j.esmoop.2022.100773. Epub 2023 Jan 10. ESMO Open. 2023. PMID: 36634532 Free PMC article. Review.
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dienstmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V. Castroviejo-Bermejo M, et al. Among authors: pellegrino b. EMBO Mol Med. 2018 Dec;10(12):e9172. doi: 10.15252/emmm.201809172. EMBO Mol Med. 2018. PMID: 30377213 Free PMC article.
My best choice after a round trip from illness.
Tommasi C, Pellegrino B, Quaini F, Musolino A. Tommasi C, et al. Among authors: pellegrino b. Acta Biomed. 2017 Aug 23;88(2):196-197. doi: 10.23750/abm.v88i2.5777. Acta Biomed. 2017. PMID: 28845836 Free PMC article.
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study.
Musolino A, Falcini F, Sikokis A, Boggiani D, Rimanti A, Pellegrino B, Silini EM, Campanini N, Barbieri E, Zamagni C, Degli Esposti R, Cortesi L, Bisagni G, Cavanna L, Frassoldati A, Sgargi P, Michiara M. Musolino A, et al. Among authors: pellegrino b. Eur J Cancer. 2018 Jan;88:10-20. doi: 10.1016/j.ejca.2017.10.024. Epub 2017 Nov 23. Eur J Cancer. 2018. PMID: 29175735
87 results